Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/computed tomography for pancreatic malignancy: A meta-analysis using a hierarchical regression model

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 1027-1035

  Wu, Lian Ming ^a   Hu, Jia Ni ^b   Hua, Jia ^a   Liu, Man Ju ^b   Chen, Jie ^a   Xu, Jian Rong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Diffusion weighted magnetic resonance imaging; Meta analysis; Pancreatic malignancy; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER DIAGNOSIS; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; EMBASE; HUMAN; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PANCREAS BIOPSY; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SYSTEMATIC REVIEW;

EID: 84861463777     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07112.x     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43-66.
2. Beyer T, Townsend DW, Brun T etal. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 2000; 41: 1369-79.
3. Bar-Shalom R, Yefremov N, Guralnik L etal. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J. Nucl. Med. 2003; 44: 1200-9.
4. Tang S, Huang G, Liu J etal. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur. J. Radiol. 2011; 78: 142-50.
5. Yamamura J, Salomon G, Buchert R etal. Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy. J. Comput. Assist. Tomogr. 2011; 35: 223-8.
6. Matsuki M, Inada Y, Tatsugami F, Tanikake M, Narabayashi I, Katsuoka Y. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur. Radiol. 2007; 17: 201-4.
7. Busard MP, Mijatovic V, van Kuijk C etal. Magnetic resonance imaging in the evaluation of (deep infiltrating) endometriosis: the value of diffusion-weighted imaging. J. Magn. Reson. Imaging 2010; 32: 1003-9.
8. Ichikawa T, Erturk SM, Motosugi U etal. High-b-value diffusion-weighted MRI in colorectal cancer. AJR Am. J. Roentgenol. 2006; 187: 181-4.
9. Bruegel M, Holzapfel K, Gaa J etal. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echoplanar MR imaging technique. Eur. Radiol. 2008; 18: 477-85.
10. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur. Radiol. 2008; 18: 486-92.
11. Mawlawi O, Erasmus JJ, Munden RF etal. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am. J. Roentgenol. 2006; 186: 308-19.
12. Pfannenberg AC, Aschoff P, Brechtel K etal. Low dose nonenhanced. CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2007; 34: 36-44.
13. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol. 2003; 3: 25-37.
14. Rutter CM, Gatsonis CA. A hierarchical regression approach to metaanalysis of diagnostic test accuracy evaluations. Stat. Med. 2001; 20: 2865-84.
15. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods 2006; 11: 193-206.
16. Saremi F, Jalili M, Sefidbakht S etal. Diffusion-weighted imaging of the abdomen at 3 T: image quality comparison with 1.5-T magnet using 3 different imaging sequences. J. Comput. Assist. Tomogr. 2011; 35: 317-25.
17. Strobel K, Heinrich S, Bhure U etal. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J. Nucl. Med. 2008; 49: 1408-13.
18. Wang Y, Chen ZE, Nikolaidis P etal. Diffusion-weighted magnetic resonance imaging of pancreatic adenocarcinomas: association with histopathology and tumor grade. J. Magn. Reson. Imaging 2011; 33: 136-42.
19. Fattahi R, Balci NC, Perman WH etal. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J. Magn. Reson. Imaging 2009; 29: 350-6.
20. Quon A, Chang ST, Chin F etal. Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 527-31.
21. Park SS, Lee KT, Lee KH etal. Diagnostic usefulness of PET/CT for pancreatic malignancy. Korean J. Gastroenterol. 2009; 54: 235-42.
22. Dupas B, Le Borgne J. MRI-cholangiopancreatography characteristics of cystic pancreatic tumors. Ann. Chir. 2000; 125: 571-7.
23. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusion-weighted MR imaging with single-shot echo-planar imaging in the upper abdomen: preliminary clinical experience in 61 patients. Abdom. Imaging 1999; 24: 456-61.
24. Yasui O, Sato M. Combined imaging with multi-detector row computed tomography and diffusion-weighted imaging in the detection of pancreatic cancer. Tohoku J. Exp. Med. 2011; 224: 195-9.
25. Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y. Usefulness of diffusion-weighted imaging (DWI) for the detection of pancreatic cancer: 4 case reports. Hepatogastroenterology 2008; 55: 282-5.
26. Takakura K, Sumiyama K, Munakata K etal. Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT. Abdom. Imaging 2011; 36: 457-62.
27. Takanami K, Hiraide T, Tsuda M etal. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann. Nucl. Med. 2011; 25: 501-10.
28. Buchs NC, Bühler L, Bucher P etal. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J. Gastroenterol. Hepatol. 2011; 26: 657-62.
29. Sandrasegaran K, Akisik FM, Patel AA etal. Diffusion-weighted imaging in characterization of cystic pancreatic lesions. Clin. Radiol. 2011; 66: 808-14.
30. Caramella C, Dromain C, De Baere T etal. Endocrine pancreatic tumours: which are the most useful MRI sequences? Eur. Radiol. 2010; 20: 2618-27.
31. Kitajima K, Murakami K, Yamasaki E etal. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol. Imaging Biol. 2010; 12: 452-9.
32. Lemke A, Laun FB, Klauss M etal. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxelincoherent motion derived parameters. Invest. Radiol. 2009; 44: 769-75.
33. Kartalis N, Lindholm TL, Aspelin P, Permert J, Albiin N. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur. Radiol. 2009; 19: 1981-90.
34. Kauhanen SP, Komar G, Seppänen MP etal. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009; 250: 957-63.
35. Lee SS, Byun JH, Park BJ etal. Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J. Magn. Reson. Imaging 2008; 28: 928-36.
36. Ichikawa T, Erturk SM, Motosugi U etal. High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR Am. J. Roentgenol. 2007; 188: 409-14.
37. Schick V, Franzius C, Beyna T etal. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1775-85.
38. Saif MW, Cornfeld D, Modarresifar H, Ojha B. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. J. Gastrointestin. Liver Dis. 2008; 17: 173-8.
39. Farma JM, Santillan AA, Melis M etal. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann. Surg. Oncol. 2008; 15: 2465-71.
40. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin. Radiol. 2007; 62: 745-51.
41. Lemke AJ, Niehues SM, Hosten N etal. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J. Nucl. Med. 2004; 45: 1279-86.
42. Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography: clinical use, interpretation methods, diagnostic improvements. Semin. Nucl. Med. 2003; 33: 228-37.
43. Schaefer NG, Hany TF, Taverna C etal. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG-PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004; 232: 823-9.
44. Luboldt W, Kufer R, Blumstein N etal. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008; 249: 1017-25.
45. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur. J. Radiol. 2009; 72: 381-7.
46. Zimny M, Bares R, Fass J etal. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur. J. Nucl. Med. 1997; 24: 678-82.
47. Bang S, Chung HW, Park SW etal. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J. Clin. Gastroenterol. 2006; 40: 923-9.
48. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210: 617-23.
49. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am. J. Roentgenol. 1999; 173: 393-8.
50. Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K. Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad. Radiol. 2007; 14: 643-50.
51. Matsuki M, Inada Y, Nakai G etal. Diffusion-weighted MR imaging of pancreatic carcinoma. Abdom. Imaging 2007; 32: 481-3.
52. Takeuchi M, Matsuzaki K, Kubo H, Nishitani H. High-b-value diffusion-weighted magnetic resonance imaging of pancreatic cancer and massforming chronic pancreatitis: preliminary results. Acta Radiol. 2008; 49: 383-6.